Journal of Pharmaceutical Analysis and Drug Research ISSN: 3108-0839 (Online)

Authors:- Dr. Satendra Singh, Gaurav Malhotra

Abstract:- Warfarin is a powerful anticoagulant that, when administered wisely and well managed, results in significant reductions in morbidity and death from thromboembolic events. Even with careful monitoring, however, the commencement of warfarin administration is linked with extremely varied reactions across individuals and difficulties obtaining and maintaining levels within the restricted therapeutic range, which can lead to adverse pharmacological events. Variations in the genes encoding the enzymes cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (CYP2C9) are the most closely connected to warfarin dosage needs (VKOR). Patients using warfarin who have one or more genetic polymorphisms in CYP2C9 and VKORC1 are more likely to experience adverse medication events and require large dosage reductions to obtain a therapeutic international normalised ratio (INR). The findings of this study imply that the CYP2C9*2 and CYP2C9*3 polymorphisms are associated with an increased risk of over anticoagulation and bleeding episodes in patients using warfarin anticoagulant, albeit the limited sample size in certain cases urges caution in interpretation. Screening for CYP2C9 variations assists doctors in developing new needed dose strategies and surveillance procedures in warfarin patients to limit the risk of adverse effects (14). The theme of this review sought to describe the role of CYP2C9*2 and CYP2C9*3 variations in anticoagulation and bleeding events in warfarin treatment.

Keywords:- Thromboembolism, CYP2CP; Dosage Adjustment, Warfarin, VKORC1